Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Morgan Stanley Raises Price Target on Gilead Sciences to $79 From $74, Keeps Equalweight Rating
Gilead Sciences Poised for Growth: A Strong Buy Rating With a $93 Price Target
Pfizer Analyst Ratings
Deutsche Bank Adjusts Price Target on Merck to $145 From $140
Daiwa Securities Upgrades Pfizer to Outperform From Neutral, Adjusts Price Target to $34 From $28
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $251
Daiwa Securities Adjusts Merck & Company Price Target to $130 From $150, Maintains Outperform Rating
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Biogen Analyst Ratings
Mizuho Maintains Outperform on Biogen, Lowers Price Target to $251
Merck KGaA Gets a Buy From Deutsche Bank
Blueprint Medicines Analyst Ratings
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
Mizuho Adjusts Biogen's Price Target to $251 From $277, Keeps Outperform Rating
Biogen Price Target Cut to $302.00/Share From $340.00 by Truist Securities
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Announces Target Price $302
Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
Daiwa Securities Adjusts Bristol-Myers Squibb Price Target to $50 From $40